[1]
|
Ang, T.L. and Fock, K.M. (2014) Clinical Epidemiology of Gastric Cancer. Singapore Medical Journal, 55, 621-628.
https://doi.org/10.11622/smedj.2014174
|
[2]
|
Lazar, D.C., Taban, S., Cornianu, M., Faur, A. and Goldis, A. (2016) New Advances in Targeted Gastric Cancer Treatment. World Journal of Gastroenterology, 22, 6776-6799. https://doi.org/10.3748/wjg.v22.i30.6776
|
[3]
|
Peddanna, N., Holt, S. and Verma, R.S. (1995) Genetics of Gastric Cancer. Anticancer Research, 15, 2055-2064.
|
[4]
|
Zhang, Z. and Hao, K. (2018) Using SAAS-CNV to Detect and Characterize Somatic Copy Number Alterations in Cancer Genomes from Next Generation Sequencing and SNP Array Data. In: Bickhart, D., Ed., Copy Number Variants. Methods in Molecular Biology, Vol. 1833, Humana Press, New York, 29-47.
https://doi.org/10.1007/978-1-4939-8666-8_2
|
[5]
|
Tomczak, K., Czerwinska, P. and Wiznerowicz, M. (2015) The Cancer Genome Atlas (TCGA): An Immeasurable Source of Knowledge. Contemporary Oncology (Pozn), 19, A68-A77. https://doi.org/10.5114/wo.2014.47136
|
[6]
|
Huang da W, Sherman, B.T. and Lempicki, R.A. (2009) Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources. Nature Protocols, 4, 44-57. https://doi.org/10.1038/nprot.2008.211
|
[7]
|
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., et al. (2015) STRING v10: Protein-Protein Interaction Networks, Integrated over the Tree of Life. Nucleic Acids Research, 43, D447-D452.
https://doi.org/10.1093/nar/gku1003
|
[8]
|
Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., et al. (2003) Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research, 13, 2498-2504.
https://doi.org/10.1101/gr.1239303
|
[9]
|
Chin, C.H., Chen, S.H., Wu, H.H., Ho, C.W., Ko, M.T. and Lin, C.Y. (2014) cytoHubba: Identifying Hub Objects and Sub-Networks from Complex Interactome. BMC Systems Biology, 8, Article No. S11.
https://doi.org/10.1186/1752-0509-8-S4-S11
|
[10]
|
Bader, G.D. and Hogue, C.W. (2003) An Automated Method for Finding Molecular Complexes in Large Protein Interaction Networks. BMC Bioinformatics, 4, Article No. 2. https://doi.org/10.1186/1471-2105-4-2
|
[11]
|
Lanczky, A., Nagy, A., Bottai, G., Munkacsy, G., Szabo, A., Santarpia, L., et al. (2016) miRpower: A Web-Tool to Validate Survival-Associated miRNAs Utilizing Expression Data from 2178 Breast Cancer Patients. Breast Cancer Research and Treatment, 160, 439-446. https://doi.org/10.1007/s10549-016-4013-7
|
[12]
|
Chandrashekar, D.S., Bashel, B., Balasubramanya, S.A.H., Creighton, C.J., Ponce-Rodriguez, I., Chakravarthi, B., et al. (2017) UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19, 649-658. https://doi.org/10.1016/j.neo.2017.05.002
|
[13]
|
Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., et al. (2013) Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling, 6, l1.
https://doi.org/10.1126/scisignal.2004088
|
[14]
|
Zhang, X., Li, M., Chen, S., Hu, J., Guo, Q., Liu, R., et al. (2018) Endoscopic Screening in Asian Countries Is Associated with Reduced Gastric Cancer Mortality: A Meta-analysis and Systematic Review. Gastroenterology, 155, 347- 354 e9. https://doi.org/10.1053/j.gastro.2018.04.026
|
[15]
|
Soussi, T. (2011) TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade. Advances in Cancer Research, 110, 107-139. https://doi.org/10.1016/B978-0-12-386469-7.00005-0
|
[16]
|
Li, V.D., Li, K.H. and Li, J.T. (2019) TP53 Mutations as Potential Prognostic Markers for Specific Cancers: Analysis of Data from the Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. Journal of Cancer Research and Clinical Oncology, 145, 625-636. https://doi.org/10.1007/s00432-018-2817-z
|
[17]
|
Wang, M., Yang, C., Zhang, X. and Li, X. (2018) Characterizing Genomic Differences of Human Cancer Stratified by the TP53 Mutation Status. Molecular Genetics and Genomics, 293, 737-746.
https://doi.org/10.1007/s00438-018-1416-7
|
[18]
|
Ando, K., Oki, E., Zhao, Y., Ikawa-Yoshida, A., Kitao, H., Saeki, H., et al. (2014) Mortalin Is a Prognostic Factor of Gastric Cancer with Normal p53 Function. Gastric Cancer, 17, 255-262. https://doi.org/10.1007/s10120-013-0279-1
|
[19]
|
Uchi, R., Kogo, R., Kawahara, K., Sudo, T., Yokobori, T., Eguchi, H., et al. (2013) PICT1 Regulates TP53 via RPL11 and Is Involved in Gastric Cancer Progression. British Journal of Cancer, 109, 2199-2206.
https://doi.org/10.1038/bjc.2013.561
|
[20]
|
Lin, Y., Wu, Z., Guo, W. and Li, J. (2015) Gene Mutations in Gastric Cancer: A Review of Recent Next-Generation Sequencing Studies. Tumor Biology, 36, 7385-7394. https://doi.org/10.1007/s13277-015-4002-1
|
[21]
|
Jiang, Z., Liu, Z., Li, M., Chen, C. and Wang, X. (2018) Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. Translational Oncology, 11, 1171-1187.
https://doi.org/10.1016/j.tranon.2018.07.012
|
[22]
|
Li, S., Balmain, A. and Counter, C.M. (2018) A Model for RAS Mutation Patterns in Cancers: Finding the Sweet Spot. Nature Reviews Cancer, 18, 767-777. https://doi.org/10.1038/s41568-018-0076-6
|
[23]
|
Chen, S., Li, F., Xu, D., Hou, K., Fang, W. and Li, Y. (2019) The Function of RAS Mutation in Cancer and Advances in its Drug Research. Current Pharmaceutical Design, 25, 1105-1114.
https://doi.org/10.2174/1381612825666190506122228
|
[24]
|
Geyer, F.C., Li, A., Papanastasiou, A.D., Smith, A., Selenica, P., Burke, K.A., et al. (2018) Recurrent Hotspot Mutations in HRAS Q61 and PI3K-AKT Pathway Genes as Drivers of Breast Adenomyoepitheliomas. Nature Communications, 9, 1816. https://doi.org/10.1038/s41467-018-04128-5
|
[25]
|
Pecenka, V., Pajer, P., Karafiat, V., Kasparova, P., Dudlova, J. and Dvorak, M. (2017) HRAS, EGFR, MET, and RON Genes Are Recurrently Activated by Provirus Insertion in Liver Tumors Induced by the Retrovirus Myeloblastosis-Associated Virus 2. Journal of Virology, 91(20). https://doi.org/10.1128/JVI.00467-17
|
[26]
|
Zhang, X. and Zhang, Y. (2015) Bladder Cancer and Genetic Mutations. Cell Biochemistry and Biophysics, 73, 65-69.
https://doi.org/10.1007/s12013-015-0574-z
|
[27]
|
Untch, B.R., Dos Anjos, V., Garcia-Rendueles, M.E.R., Knauf, J.A., Krishnamoorthy, G.P., Saqcena, M., et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Research, 78, 4642-4657.
https://doi.org/10.1158/0008-5472.CAN-17-1925
|
[28]
|
Wu, X.Y., Liu, W.T., Wu, Z.F., Chen, C., Liu, J.Y., Wu, G.N., et al. (2016) Identification of HRAS as Cancer-Pro- moting Gene in Gastric Carcinoma Cell Aggressiveness. American Journal of Cancer Research, 6, 1935-1948.
|
[29]
|
Jhanwar-Uniyal, M. (2003) BRCA1 in Cancer, Cell Cycle and Genomic Stability. Frontiers in Bioscience, 8, s1107- s1117. https://doi.org/10.2741/1131
|
[30]
|
Somasundaram, K. (2003) Breast Cancer Gene 1 (BRCA1): Role in Cell Cycle Regulation and DNA Repair—Perhaps through Transcription. Journal of Cellular Biochemistry, 88, 1084-1091.
|
[31]
|
Paul, A. and Paul, S. (2014) The Breast Cancer Susceptibility Genes (BRCA) in Breast and Ovarian Cancers. Frontiers in Bioscience (Landmark Ed), 19, 605-618.
|
[32]
|
Oh, M., McBride, A., Yun, S., Bhattacharjee, S., Slack, M., Martin, J.R., et al. (2018) BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 110, 1178-1189. https://doi.org/10.1093/jnci/djy148
|
[33]
|
Wang, G.H., Zhao, C.M., Huang, Y., Wang, W., Zhang, S. and Wang, X. (2018) BRCA1 and BRCA2 Expression Patterns and Prognostic Significance in Digestive System Cancers. Human Pathology, 71, 135-144.
https://doi.org/10.1016/j.humpath.2017.10.032
|
[34]
|
Chen, X.R., Zhang, W.Z., Lin, X.Q. and Wang, J.W. (2006) Genetic Instability of BRCA1 Gene at Locus D17S855 Is Related to Clinicopathological Behaviors of Gastric Cancer from Chinese Population. World Journal of Gastroenterology, 12, 4246-4249. https://doi.org/10.3748/wjg.v12.i26.4246
|
[35]
|
Shim, H.J., Yun, J.Y., Hwang, J.E., Bae, W.K., Cho, S.H., Lee, J.H., et al. (2010) BRCA1 and XRCC1 Polymorphisms Associated with Survival in Advanced Gastric Cancer Treated with Taxane and Cisplatin. Cancer Science, 101, 1247- 1254. https://doi.org/10.1111/j.1349-7006.2010.01514.x
|
[36]
|
Noorolyai, S., Shajari, N., Baghbani, E., Sadreddini, S. and Baradaran, B. (2019) The Relation between PI3K/AKT Signalling Pathway and Cancer. Gene, 698, 120-128. https://doi.org/10.1016/j.gene.2019.02.076
|
[37]
|
Mayer, I.A. and Arteaga, C.L. (2016) The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine, 67, 11-28. https://doi.org/10.1146/annurev-med-062913-051343
|
[38]
|
Liu, X., Xu, Y., Zhou, Q., Chen, M., Zhang, Y., Liang, H., et al. (2018) PI3K in Cancer: Its Structure, Activation Modes and Role in Shaping Tumor Microenvironment. Future Oncology, 14, 665-674. https://doi.org/10.2217/fon-2017-0588
|
[39]
|
Sobral-Leite, M., Salomon, I., Opdam, M., Kruger, D.T., Beelen, K.J., van der Noort, V., et al. (2019) Cancer-Immune Interactions in ER-Positive Breast Cancers: PI3K Pathway Alterations and Tumor-Infiltrating Lymphocytes. Breast Cancer Research, 21, Article No. 90. https://doi.org/10.1186/s13058-019-1176-2
|
[40]
|
Stachler, M.D., Rinehart, E.M., Garcia, E. and Lindeman, N.I. (2016) PIK3CA Mutations Are Common in Many Tumor Types and Are Often Associated with Other Driver Mutations. Applied Immunohistochemistry & Molecular Morphology, 24, 313-319. https://doi.org/10.1097/PAI.0000000000000195
|
[41]
|
Alvarez-Cubero, M.J., Martinez-Gonzalez, L.J., Robles-Fernandez, I., Martinez-Herrera, J., Garcia-Rodriguez, G., Pascual-Geler, M., et al. (2017) Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine. Molecular Diagnosis & Therapy, 21, 167-178. https://doi.org/10.1007/s40291-016-0248-6
|
[42]
|
Huang, D., Sun, W., Zhou, Y., Li, P., Chen, F., Chen, H., et al. (2018) Mutations of Key Driver Genes in Colorectal Cancer Progression and Metastasis. Cancer and Metastasis Reviews, 37, 173-187.
https://doi.org/10.1007/s10555-017-9726-5
|
[43]
|
Liu, S., Tang, Y., Yan, M. and Jiang, W. (2018) PIK3CA Mutation Sensitizes Breast Cancer Cells to Synergistic Therapy of PI3K Inhibition and AMPK Activation. Investigational New Drugs, 36, 763-772.
https://doi.org/10.1007/s10637-018-0563-3
|
[44]
|
Zhang, H. and Zhou, L. (2019) Single Nucleotide Polymorphism of PIK3CA and Its Interaction with the Environment Are Risk Factors for Chinese Han Ovarian Cancer. Pathology—Research and Practice, 215, 152520.
https://doi.org/10.1016/j.prp.2019.152520
|
[45]
|
Jang, S.H., Kim, K.J., Oh, M.H., Lee, J.H., Lee, H.J., Cho, H.D., et al. (2016) Clinicopathological Significance of Elevated PIK3CA Expression in Gastric Cancer. Journal of Gastric Cancer, 16, 85-92.
https://doi.org/10.5230/jgc.2016.16.2.85
|
[46]
|
Polom, K., Marrelli, D., Roviello, G., Pascale, V., Voglino, C., Vindigni, C., et al. (2018) PIK3CA Mutation in Gastric Cancer and the Role of Microsatellite Instability Status in Mutations of Exons 9 and 20 of the PIK3CA Gene. Advances in Clinical and Experimental Medicine, 27, 963-969.
|
[47]
|
Shen, X., Zhao, Y., Chen, X., Sun, H., Liu, M., Zhang, W., et al. (2019) Associations of PIK3CA Mutations with Clinical Features and Prognosis in Gastric Cancer. Future Oncology, 15, 1873-1894. https://doi.org/10.2217/fon-2018-0335
|
[48]
|
Song, M., Bode, A.M., Dong, Z. and Lee, M.H. (2019) AKT as a Therapeutic Target for Cancer. Cancer Research, 79, 1019-1031. https://doi.org/10.1158/0008-5472.CAN-18-2738
|
[49]
|
LoPiccolo, J., Granville, C.A., Gills, J.J. and Dennis, P.A. (2007) Targeting Akt in Cancer Therapy. Anticancer Drugs, 18, 861-874.
|
[50]
|
Petrini, I., Lencioni, M., Vasile, E., Fornaro, L., Belluomini, L., Pasquini, G., et al. (2018) EGFR and AKT1 Overexpression Are Mutually Exclusive and Associated with a Poor Survival in Resected Gastric Adenocarcinomas. Cancer Biomarkers, 21, 731-741. https://doi.org/10.3233/CBM-170865
|
[51]
|
Ghatak, S., Lalnunhlimi, S., Lalrohlui, F., Pautu, J.L., Zohmingthanga, J., Kunnumakkara, A.B., et al. (2018) Novel AKT1 Mutations Associated with Cell-Cycle Abnormalities in Gastric Carcinoma. Personalized Medicine, 15, 79-86.
https://doi.org/10.2217/pme-2017-0053
|
[52]
|
Hargreaves, D.C. and Crabtree, G.R. (2011) ATP-Dependent Chromatin Remodeling: Genetics, Genomics and Mechanisms. Cell Research, 21, 396-420. https://doi.org/10.1038/cr.2011.32
|
[53]
|
Khavari, P.A., Peterson, C.L., Tamkun, J.W., Mendel, D.B. and Crabtree, G.R. (1993) BRG1 Contains a Conserved Domain of the SWI2/SNF2 Family Necessary for Normal Mitotic Growth and Transcription. Nature, 366, 170-174.
https://doi.org/10.1038/366170a0
|
[54]
|
Glaros, S., Cirrincione, G.M., Palanca, A., Metzger, D. and Reisman, D. (2008) Targeted Knockout of BRG1 Potentiates Lung Cancer Development. Cancer Research, 68, 3689-3696. https://doi.org/10.1158/0008-5472.CAN-07-6652
|
[55]
|
Buscarlet, M., Krasteva, V., Ho, L., Simon, C., Hebert, J., Wilhelm, B., et al. (2014) Essential Role of BRG, the ATPase Subunit of BAF Chromatin Remodeling Complexes, in Leukemia Maintenance. Blood, 123, 1720-1728.
https://doi.org/10.1182/blood-2013-02-483495
|
[56]
|
Wu, Q., Madany, P., Akech, J., Dobson, J.R., Douthwright, S., Browne, G., et al. (2015) The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. Journal of Cellular Physiology, 230, 2683-2694.
|
[57]
|
Laurette, P., Coassolo, S., Davidson, G., Michel, I., Gambi, G., Yao, W., et al. (2020) Chromatin Remodellers Brg1 and Bptf Are Required for Normal Gene Expression and Progression of Oncogenic Braf-Driven Mouse Melanoma. Cell Death & Differentiation, 27, 29-43. https://doi.org/10.1038/s41418-019-0333-6
|